OakChart

BioNexus Gene Lab Corp

BGLCBasic Materials·Specialty Chemicals·Malaysia·Nano·NASD·Nov 11 • 4:00 PM ET

0.8589+0.0389 (4.74%)
2026-11-11 22:38 CET
Market cap
2.41 USD m
Revenue, TTM
3.13 USD m
Net income, TTM
-2.58 USD m
Free cash flow, TTM
-0.87 USD m
EPS diluted, TTM
-1.26
P/E
-
Compare

Price

BGLC against its 20, 50 and 200-day averages
2050200
1.002.003.004.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BGLCclose 0.8620-day 1.0450-day 1.25200-day 1.890.86

84.1% under the 52-week high of 5.41 on 10 Nov 2025. 52-week low 0.81 on 10 Nov 2026. Last 15 sessions, 46.9% high to low

Volume 1.41× normal · the line is the 50-bar volume average

Profile

BGLC
52-week range, 1% of the way up
0.815.15

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

Employees16
IPOSep 16, 2020
Beta1.97
ATR, 14d0.08
Rel volume1.41
Short float0.20%
Insider own46.92%
Inst own0.50%

Snapshot

6 groups

Valuation

Index-
Market Cap2.52M
Enterprise Value-0.80M
Income-2.58M
Sales3.13M
Book/sh3.22
Cash/sh1.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOSep 16, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S0.81
P/B0.27
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-0.25
Quick Ratio5.28
Current Ratio6.08
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.26
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-86.65% -
Sales past 3/5Y-12.09% -8.20%
EPS Y/Y TTM22.76%
Sales Y/Y TTM-67.27%
EPS Q/Q65.45%
Sales Q/Q-96.63%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own46.92%
Insider Trans0.00%
Inst Own0.50%
Inst Trans2.38%
ROA-28.38%
ROE-33.66%
ROIC-32.54%
Gross Margin10.73%
Oper. Margin-87.18%
Profit Margin-82.36%
SMA20-17.52%
SMA50-31.34%
SMA200-54.46%
Trades-

Technical

Shs Outstand2.42M
Shs Float1.56M
Short Float0.20%
Short Ratio0.39
Short Interest0.00M
52W High5.15 -83.32%
52W Low0.81 6.01%
Volatility5.95% 5.35%
ATR (14)0.08
RSI (14)33.45
Beta1.97
Rel Volume1.41
Avg Volume8.25K
Volume11,678

Performance

Perf Week-8.63%
Perf Month-34.93%
Perf Quarter-47.63%
Perf Half Y-56.51%
Perf YTD-78.26%
Perf Year-83.32%
Perf 3Y-73.98%
Perf 5Y-99.63%
Perf 10Y-
Recom-
Target Price-
Prev Close0.82
Price0.86
Change %4.74%

Peers

Mkt cap
TickerCompanyMkt cap
HWKNHawkins Inc3.16B
NPTTexxon Holding Ltd38.83M
YMATJ-Star Holding Co Ltd5.88M
ACNTAscent Industries Co121.70M
CMTCore Molding Technologies187.87M
FSIFlexible Solutions International Inc82.91M
NTICNorthern Technologies International Corp70.75M
GUREGulf Resources Inc5.17M
ALPSALPS Group Inc37.70M
WGSGeneDx Holdings Corp1.65B

News

latest 14 of 64
  • BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific (GlobeNewswire) -5.44%
  • BioNexus Launches New Corporate Website with Expanded Business and Investor Resources (GlobeNewswire) -6.38%
  • BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence (GlobeNewswire) +8.06%
  • BioNexus Advances VitaGuard Southeast Asia Rollout Following China Working Visit (GlobeNewswire)
  • BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development (GlobeNewswire)
  • BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform (GlobeNewswire)
  • BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman (GlobeNewswire)
  • BioNexus Launches Regional Deployment of VitaGuard MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market (GlobeNewswire)
  • BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard (GlobeNewswire)
  • BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization (GlobeNewswire)
  • BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard MRD Platform as Part of Strategic Alliance with Tongshu Gene (GlobeNewswire)
  • BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization (GlobeNewswire) -6.02%
  • BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities (GlobeNewswire)
  • BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.1990.042-0.3421.2760.527-0.247-1.656-0.897-1.608-1.261
Period201720182019202020212022202320242025TTM
EPS, quarterly0.113-0.749-0.194-0.347-0.343-0.395-0.523-0.225-0.119
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.1080.2120.12711.3913.36310.9299.7719.5117.4253.13
Period201720182019202020212022202320242025TTM
Sales, quarterly1.9752.632.5242.1372.262.5440.4840.0230.076
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6220.6220.8561.4271.4271.4481.7671.7972.4172.417
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.7671.7971.7971.7971.7971.7972.4172.4172.417
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.137.429.519.7710.9313.3611.390.130.21
Cost of Goods Sold Incl. D&A2.796.458.338.529.7611.269.760.070.18
Gross Profit0.340.971.191.251.172.101.630.060.03
Selling, General and Administrative Excl. Other3.064.133.144.331.641.111.240.360.24
Research and Development0.050.050.050.05-----
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-2.73-3.16-1.96-3.08-0.470.990.39-0.30-0.21
Interest Expense0.020.020.020.010.010.010.01-0.00
Unusual Expense0.000.09-0.07-0.310.000.000.000.000.00
Net Income Before Taxes-2.58-2.98-1.59-2.61-0.301.041.26-0.280.06
Income Taxes0.000.000.000.020.050.290.17-0.030.03
Consolidated Net Income-2.58-2.98-1.60-2.63-0.360.751.09-0.250.03
Net Income From Continuing Operations-2.58-2.98-1.60-2.63-0.360.751.09-0.250.03
Net Income-2.58-2.98-1.60-2.63-0.360.751.09-0.250.03
EPS (Recurring)-1.06-1.57-0.92-1.79-0.250.531.28-0.340.04
EPS (Basic, Before Extraordinaries)-1.26-1.61-0.90-1.66-0.250.531.28-0.340.04
EPS (Diluted)-1.26-1.61-0.90-1.66-0.250.531.28-0.340.04
EBITDA-2.55-2.99-1.80-2.97-0.371.100.49-0.25-0.17
Non-Operating Income (Expense)0.170.290.310.180.180.070.890.030.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.630.11------
Price To Earnings Ratio-----40.4318.03--
Price To Sales Ratio1.510.990.520.8615.0327.2920.78--
Gross Margin10.7313.1112.4612.7510.6815.7314.3044.0213.55
Operating Margin-87.18-42.54-20.57-31.52-4.307.403.40-236.90-100.39
Net Margin-82.36-40.20-16.81-26.91-3.265.629.61-194.1412.46
Shares Outstanding2.422.421.801.771.451.431.430.860.62
Market Capitalization2.412.410.420.7913.7530.3932.8219.69-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.080.020.482.542.262.142.522.63
Cost of Goods Sold Incl. D&A0.060.050.522.171.891.792.242.34
Gross Profit0.01-0.02-0.030.380.370.340.280.29
Selling, General and Administrative Excl. Other0.330.551.001.191.070.96-0.322.10
Research and Development0.010.010.010.010.010.010.05-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.31-0.57-1.03-0.81-0.70-0.620.60-1.80
Interest Expense0.000.000.000.010.000.000.010.01
Unusual Expense0.000.000.000.000.030.06-0.070.00
Net Income Before Taxes-0.29-0.54-1.04-0.71-0.62-0.62-0.42-1.34
Income Taxes0.000.000.000.000.000.00-0.070.00
Consolidated Net Income-0.29-0.54-1.04-0.71-0.62-0.62-0.35-1.35
Net Income From Continuing Operations-0.29-0.54-1.04-0.71-0.62-0.62-0.35-1.35
Net Income-0.29-0.54-1.04-0.71-0.62-0.62-0.35-1.35
EPS (Recurring)-0.12-0.22-0.52-0.39-0.33-0.32-0.22-0.75
EPS (Basic, Before Extraordinaries)-0.12-0.22-0.52-0.39-0.34-0.35-0.19-0.75
EPS (Diluted)-0.12-0.22-0.52-0.39-0.34-0.35-0.19-0.75
EBITDA-0.27-0.53-0.99-0.77-0.66-0.580.64-1.75
Non-Operating Income (Expense)0.030.030.000.110.120.06-1.080.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio1.510.971.051.040.580.460.530.86
Gross Margin17.05-99.51-6.7014.8516.2816.0711.0811.11
Operating Margin-409.71-2,501.68-213.33-31.85-30.97-28.8323.70-68.55
Net Margin-376.14-2,379.72-214.18-27.87-27.26-29.17-13.80-51.15
Shares Outstanding2.422.422.421.801.801.801.801.80
Market Capitalization2.413.857.109.835.520.350.420.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.044.385.932.122.122.790.861.260.84
Short Term Receivables0.571.460.862.903.364.000.000.000.00
Inventories0.681.391.140.981.521.180.010.020.03
Other Current Assets0.170.200.120.030.080.020.010.020.13
Total Current Assets5.457.438.056.027.087.990.881.301.00
Net Property, Plant & Equipment1.781.741.651.571.681.850.340.340.27
Total Investments and Advances2.031.271.701.150.750.280.010.010.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.070.000.000.000.00
Total Assets9.2510.4311.408.749.5710.121.231.651.27
Short Term Debt Incl. Current Port. of LT Debt0.060.050.030.020.040.050.030.020.00
Accounts Payable0.001.501.401.862.013.170.000.001.17
Income Tax Payable---0.000.100.060.000.03-
Other Current Liabilities0.460.400.190.130.180.100.020.010.00
Total Current Liabilities0.521.951.632.002.333.370.050.061.17
Long Term Debt0.120.160.100.040.040.080.060.060.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--0.010.030.030.00-0.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities0.642.111.742.082.393.450.110.131.18
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity8.618.329.666.677.186.661.121.520.09
Total Shareholders Equity8.618.329.666.677.186.661.121.520.09
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity8.618.329.666.677.186.661.121.520.09
Total Liabilities & Stockholders Equity9.2510.4311.408.749.5710.121.231.651.27
Book Value Per Share3.564.635.474.605.034.671.312.450.15
Tangible Book Value Per Share3.564.635.474.605.034.671.312.450.15
Full-Time Employees16303018135---
Price to Book Ratio0.250.050.082.144.234.9321.14--
Return on Assets-30.32-14.64-26.11-3.897.6319.29-17.101.81-19.44
Return on Equity-35.24-17.78-32.21-5.1410.8628.11-18.643.27-265.23
Return on Invested Capital-34.18-18.84-26.95-5.3110.4116.23-20.891.67-130.78
Quick Ratio9.163.104.242.522.392.0216.9720.400.82
Current Ratio10.463.814.933.003.042.3717.1120.640.85

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-2.58-2.98-1.60-2.63-0.360.751.09-0.250.03
Depreciation0.180.170.150.110.110.110.100.050.04
Other Funds (Non Cash)1.100.99-0.700.640.080.03-0.74-0.00
Funds from Operations-1.29-1.83-2.14-1.88-0.170.890.46-0.190.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.450.010.120.120.83-0.860.10-0.02-0.34
Income Taxes Payable------0.03--
Cash from Operating Activities-0.84-1.82-2.03-1.760.660.030.56-0.22-0.27
Capital Expenditures-0.03-0.04-0.23-0.15-0.05-0.00-0.42-0.01-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.001.810.000.00
Purchase or Sale of Investments1.451.020.58-0.29-0.51-0.51-0.080.00-0.01
Purchase of Investments-0.03-0.01-0.49-0.32-0.51-0.52-0.110.00-0.01
Sale Or Maturity of Investments1.481.031.070.030.000.010.030.000.00
Other Uses-0.03-0.06-0.08-1.410.000.000.000.000.00
Other Sources0.000.000.080.000.000.000.000.000.00
Cash from Investing Activities1.390.920.35-1.86-0.57-0.511.31-0.01-0.05
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.270.270.005.750.000.000.000.000.74
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.270.270.005.750.000.000.000.000.74
Proceedsfrom Stock Options0.270.270.005.750.000.000.000.000.74
Issuance or Reduction of Debt, Net-0.000.000.000.00-0.03-0.03-0.00-0.020.00
Change in Long Term Debt-0.000.000.000.00-0.030.00-0.00-0.020.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.00-0.030.00-0.00-0.020.00
Net Financing Active Other Cash Flow0.110.030.000.520.15-0.000.00-0.160.00
Other Financing Activities Uses--0.000.000.000.00-0.000.00-0.160.00
Cash from Financing Activities0.370.300.006.270.12-0.03-0.00-0.180.74
Exchange Rate Effect-0.060.190.04-0.26-0.21-0.150.060.010.00
Net Change in Cash0.85-0.40-1.632.40-0.01-0.661.93-0.400.42
Free Cash Flow-0.87-1.85-2.25-1.910.610.030.14-0.23-0.31
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----271.4313,024.811,722.79--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.523.964.042.893.063.60
Short Term Receivables0.080.140.571.631.951.53
Inventories0.650.670.681.011.221.18
Other Current Assets0.690.420.170.100.150.24
Total Current Assets4.945.205.455.636.386.54
Net Property, Plant & Equipment1.761.821.781.761.791.72
Total Investments and Advances2.032.032.030.241.251.21
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets-12.16----
Other Assets0.000.000.000.000.000.00
Total Assets8.7321.209.257.629.429.48
Short Term Debt Incl. Current Port. of LT Debt0.060.070.060.060.060.05
Accounts Payable0.010.000.000.181.371.18
Other Current Liabilities0.740.730.460.440.330.33
Total Current Liabilities0.810.800.520.681.761.56
Long Term Debt0.140.150.120.130.140.15
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities-12.16----
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.9513.110.640.801.901.71
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.788.098.616.827.527.77
Total Shareholders Equity7.788.098.616.827.527.77
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.788.098.616.827.527.77
Total Liabilities & Stockholders Equity8.7321.209.257.629.429.48
Book Value Per Share3.223.353.563.794.194.33
Tangible Book Value Per Share3.223.353.563.794.194.33
Full-Time Employees--16---
Price to Book Ratio0.250.561.041.310.710.05
Return on Assets-28.38-18.94-30.32-24.68-28.53-20.52
Return on Equity-33.66-36.62-35.24-28.35-34.37-24.75
Return on Invested Capital-3.62-6.59-11.87-10.21-8.04-7.87
Quick Ratio5.285.699.166.812.943.44
Current Ratio6.086.5210.468.303.634.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.29-0.54-1.04-0.71-0.62-0.62
Depreciation0.050.040.040.040.040.04
Other Funds (Non Cash)-0.020.180.800.15-0.040.08
Funds from Operations-0.26-0.32-0.19-0.52-0.62-0.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.160.181.15-0.72-0.11-0.31
Income Taxes Payable0.00-0.00----
Cash from Operating Activities-0.42-0.150.96-1.23-0.73-0.82
Capital Expenditures-0.02-0.00-0.00-0.01-0.02-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.420.000.011.010.000.00
Purchase of Investments-0.020.00-0.00-0.010.000.00
Sale Or Maturity of Investments0.440.000.011.020.000.00
Other Uses0.01-0.01-0.02-0.02-0.02-0.02
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.42-0.01-0.010.99-0.04-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.270.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.270.000.000.00
Proceedsfrom Stock Options0.000.000.270.000.000.00
Issuance or Reduction of Debt, Net0.02-0.020.000.000.000.00
Change in Long Term Debt0.02-0.020.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.02-0.020.000.000.000.00
Net Financing Active Other Cash Flow-0.010.08-0.000.03-0.00-0.00
Other Financing Activities Uses---0.000.00-0.00-0.00
Cash from Financing Activities0.010.060.270.03-0.00-0.00
Exchange Rate Effect-0.010.01-0.090.030.220.04
Net Change in Cash-0.01-0.091.13-0.18-0.55-0.80
Free Cash Flow-0.44-0.150.96-1.24-0.75-0.82

Revenue breakdown

Bangladesh2024: 123.27K 2025: 106.25K
Indonesia2024: 138.30K 2025: 114.87K
Malaysia2024: 7.46M 2025: 5.83M
Maldives2024: 762.14K 2025: 680.99K
Singapore2024: 572.03K 2025: 240.76K
Sri Lanka2024: 459.00K 2025: 452.64K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.20%0.0M1.6M9.72K
2026-10-150.58%0.0M1.6M11.50K
2026-09-300.65%0.0M1.6M10.22K
2026-09-150.84%0.0M1.6M12.71K
2026-08-310.48%0.0M1.6M94.87K
2026-08-140.58%0.0M1.3M101.37K
2026-07-310.41%0.0M1.6M99.61K
2026-07-150.22%0.0M1.6M101.07K
2026-06-300.94%0.0M1.6M98.97K
2026-06-156.36%0.1M1.6M95.12K
2026-05-291.43%0.0M1.6M13.14K
2026-05-150.68%0.0M1.6M5.81K
2026-04-300.64%0.0M1.6M13.17K
2026-04-150.64%0.0M1.6M20.46K
2026-03-312.05%0.0M1.2M21.19K
2026-03-131.96%0.0M1.2M22.97K
2026-02-272.35%0.0M1.2M85.27K
2026-02-131.42%0.0M1.2M85.70K
2026-01-301.50%0.0M1.2M116.37K
2026-01-151.47%0.0M1.2M133.59K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-22SCHEDULE 13GSEC
2026-10-078-KCurrent report2026-10-05SEC
2026-08-14SCHEDULE 13DSEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-073Initial statement of beneficial ownership of securities2025-11-28SEC
2026-07-313Initial statement of beneficial ownership of securities2023-08-15SEC
2026-07-313Initial statement of beneficial ownership of securities2023-12-11SEC
2026-07-313Initial statement of beneficial ownership of securities2022-03-07SEC
2026-07-313Initial statement of beneficial ownership of securities2025-06-17SEC
2026-07-313Initial statement of beneficial ownership of securities2025-06-17SEC
2026-07-288-KCurrent report2026-07-28SEC
2026-06-058-KCurrent report2026-05-29SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-1410-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-31NT 10-K2025-12-31SEC
2026-03-178-KCurrent report2026-03-11SEC
2026-02-238-KCurrent report2026-02-23SEC
2026-02-038-KCurrent report2026-01-28SEC
2025-12-308-KCurrent report2025-12-24SEC
2025-12-238-KCurrent report2025-12-19SEC
2025-12-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-24SEC
2025-12-028-KCurrent report2025-11-28SEC
2025-11-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-11-14SEC
2025-11-138-KCurrent report2025-11-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP0.59%
UBS Group AG0.01%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.10%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. BGLC. Cached 15 minutes.

Some panels did not load: ratings, insider.